• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development

    7/17/24 7:30:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials
    Get the next $DHR alert in real time by email
    • DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.
    • Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.

    WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher"), a global science and technology innovator, announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (CDx) and Complementary Diagnostics (CoDx).

    "Our investments in these centers of innovation uniquely position Danaher as a global connector across the innovation ecosystem, leveraging diagnostic technology to simplify and speed pharma translational research," said Julie Sawyer Montgomery, Executive Vice President at Danaher. "I am excited about this new way of potentially enabling our partners to more quickly bring precision treatments to market – ultimately benefiting more patients everywhere." 

    "The pharmaceutical industry needs a new, holistic approach that minimizes time-consuming assay format transfers and contracts across every step, from biomarker validation to clinical trial assays and companion and complementary diagnostics, to global deployment, education, and adoption," said Amit Agrawal, Chief Scientific Officer, DH Diagnostics LLC. "I believe our new approach to catalyzing development of meaningful diagnostics has the potential to bring us significantly closer to realizing the potential of precision medicine to deliver the right medicine for the right patient at the right time."

    CDx and CoDx tests enable patients to receive targeted therapies intended to better treat their disease. CDx tests are designed to determine whether a patient produces enough of a particular protein to respond well to a specific drug. CoDx tests highlight broadly which type of therapy may be most helpful to a patient. For patients undergoing cancer treatment, this diagnostic process can make a significant difference in prognosis.

    Today, the development process for CDx and CoDx from discovery to FDA approval can be lengthy, requiring an average of 15 hand-offs as studies move from research-grade to clinical. Danaher's centers of innovation will seek to drive efficiencies within this ecosystem by minimizing hand-offs and bringing multi-modal capabilities under one roof. Danaher's installed base of instruments in more than 30,000 hospitals in 120 countries offers the potential to further facilitate faster commercialization of personalized treatment for patients.

    Danaher's first CLIA CAP* lab, scheduled to open in July in Newcastle, UK, will serve as a hub for collaborative research with leading pharmaceutical and academic institutions. Leica Biosystems, a global leader in anatomic pathology and a Danaher subsidiary, is hosting the lab in a state-of-the-art new building on its campus.

    In parallel, Danaher's additional center of innovation, located in the United States, is scheduled to open its doors later this year and include capabilities such as immunohistochemistry (IHC), polymerase chain reaction (PCR) and immunoassay. Instrumentation from several Danaher subsidiaries including Cepheid, Beckman Coulter Diagnostics, and Leica Biosystems will be available in this lab, with additional capabilities from other subsidiaries to join in the future. Further modalities such as next-generation sequencing (NGS) are available via Danaher's subsidiaries and strategic partners.

    *CAP CLIA certifications pending

    ABOUT DANAHER

    Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

    FORWARD-LOOKING STATEMENTS

    Statements in this release that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. Information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2023 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2024. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, Danaher does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

    Cision View original content:https://www.prnewswire.com/news-releases/danaher-announces-two-new-centers-of-innovation-in-diagnostics-to-transform-precision-medicine-development-302198969.html

    SOURCE Danaher Corporation

    Get the next $DHR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DHR

    DatePrice TargetRatingAnalyst
    7/11/2025$275.00Sector Perform → Sector Outperform
    Scotiabank
    4/10/2025$205.00Equal Weight → Overweight
    Barclays
    3/21/2025$260.00Neutral → Buy
    Goldman
    3/14/2025$260.00Hold → Buy
    Stifel
    2/3/2025Outperform → Mkt Perform
    Raymond James
    12/23/2024Sector Perform
    Scotiabank
    12/19/2024$275.00Buy
    Guggenheim
    12/13/2024$290.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $DHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Danaher upgraded by Scotiabank with a new price target

      Scotiabank upgraded Danaher from Sector Perform to Sector Outperform and set a new price target of $275.00

      7/11/25 7:56:02 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher upgraded by Barclays with a new price target

      Barclays upgraded Danaher from Equal Weight to Overweight and set a new price target of $205.00

      4/10/25 8:28:29 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher upgraded by Goldman with a new price target

      Goldman upgraded Danaher from Neutral to Buy and set a new price target of $260.00

      3/21/25 8:01:35 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director List Teri exercised 3,928 shares at a strike of $59.34 and covered exercise/tax liability with 1,150 shares, increasing direct ownership by 13% to 23,517 units (SEC Form 4)

      4 - DANAHER CORP /DE/ (0000313616) (Issuer)

      7/7/25 5:00:12 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • New insider Milosevich Gregory M claimed ownership of 4,455 shares (SEC Form 3)

      3 - DANAHER CORP /DE/ (0000313616) (Issuer)

      7/1/25 5:00:51 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Director Stevens Raymond C was granted 577 shares, increasing direct ownership by 5% to 12,361 units (SEC Form 4)

      4 - DANAHER CORP /DE/ (0000313616) (Issuer)

      5/19/25 5:02:20 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    SEC Filings

    See more
    • SEC Form 11-K filed by Danaher Corporation

      11-K - DANAHER CORP /DE/ (0000313616) (Filer)

      6/17/25 8:19:40 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SEC Form SD filed by Danaher Corporation

      SD - DANAHER CORP /DE/ (0000313616) (Filer)

      5/12/25 4:39:59 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - DANAHER CORP /DE/ (0000313616) (Filer)

      5/8/25 4:36:17 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact. "Danaher i

      6/27/25 7:35:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. "Greg has played a pivotal role in advancing our Life Sciences Innovations Group over the past f

      6/27/25 7:30:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Schedules Second Quarter 2025 Earnings Conference Call

      WASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You

      6/17/25 4:30:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Financials

    Live finance-specific insights

    See more
    • Danaher Schedules Second Quarter 2025 Earnings Conference Call

      WASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You

      6/17/25 4:30:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Announces Quarterly Dividend

      WASHINGTON, May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and h

      5/6/25 4:15:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Reports First Quarter 2025 Results

      WASHINGTON, April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88.Revenues decreased 1.0% to $5.7 billion and non-GAAP core revenue was flat year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "Revenue, earnings, and cash flow exceeded our expectations in the first quarter–highlighted by continued momentum in bioprocessing and better-

      4/22/25 6:00:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $DHR
    Leadership Updates

    Live Leadership Updates

    See more
    • Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact. "Danaher i

      6/27/25 7:35:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. "Greg has played a pivotal role in advancing our Life Sciences Innovations Group over the past f

      6/27/25 7:30:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Announces Appointment of Charles Lamanna to Danaher Board

      WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ:MSFT), where he drives product innovation in AI-powered business applications, low-code platforms, and autonomous agents. He oversees the design, product development, and engineering of some of Microsoft's most transformative technologies, including Power Platform, Dynamics 365, and Copilot Studio. Prior to that, Mr. Lamanna was the founder and CEO of MetricsHub, one of the first public cloud

      2/20/25 4:45:00 PM ET
      $DHR
      $MSFT
      Industrial Machinery/Components
      Industrials
      Computer Software: Prepackaged Software
      Technology

    $DHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

      SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

      2/9/23 11:16:32 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

      SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

      2/9/22 3:43:35 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D/A filed by Danaher Corporation (Amendment)

      SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)

      11/2/21 9:29:29 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials